Inari Medical Announces PEERLESS Data To Be Presented During The Late-Breaking Clinical Trial Sessions At TCT 2024
Portfolio Pulse from Benzinga Newsdesk
Inari Medical will present data from the PEERLESS trial at the TCT 2024 symposium. The trial compares the FlowTriever system to catheter-directed thrombolysis for treating intermediate-risk pulmonary embolism, providing crucial insights for clinicians.
August 29, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inari Medical will present PEERLESS trial data at TCT 2024, comparing its FlowTriever system to traditional treatments for pulmonary embolism. This could influence clinician adoption and market perception of Inari's products.
The presentation of the PEERLESS trial data at a major symposium like TCT 2024 is significant for Inari Medical. Positive trial results could enhance the credibility and adoption of the FlowTriever system among clinicians, potentially boosting sales and market share. This event is likely to generate interest and could positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90